IP Library Granted Patent US 10,344,289
Granted Patent B2
US 10,344,289 · App. 14/538,609 · Granted Jul 9, 2019

Engineered zinc finger proteins targeting 5-enolpyruvyl shikimate-3-phosphate synthase genes

Inventors: Manju Gupta (Indianapolis, IN); Asha M. Palta (Indianapolis, IN); Stephen Novak (Indianapolis, IN); Fyodor Urnov (Richmond, CA); Sunita Gopalan (Richmond, CA)
Assignees: Dow AgroSciences LLC; Sangamo Therapeutics, Inc.
C12N15/8213C12N9/1092C12N15/8243C12N15/8274C07K2319/00C07K2319/81
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,344,289
App. No.
14/538,609
Granted
Jul 9, 2019
Kind
B2
Abstract

The present disclosure relates to engineered zinc finger proteins that target 5-enolpyruvyl shikimate-3-phosphate synthase (EPSPS) genes in plants and methods of using such zinc finger proteins in modulating gene expression, gene inactivation, and targeted gene modification. In particular, the disclosure pertains to zinc finger nucleases for targeted cleavage and alteration of EPSPS genes.

Claims (10)

1. A method for stimulating homologous recombination in the genome of a plant cell, the method comprising the step of:

introducing a zinc finger nuclease (ZFN) into the plant cell in the presence of a DNA segment in the plant cell, wherein the DNA segment comprises at least one target site in an 5-enolpyruvyl shikimate-3-phosphate synthase (EPSPS) gene, wherein said target site comprises any one of SEQ ID NO: 141-153, wherein the ZFN cleaves the DNA segment and stimulates homologous recombination, wherein the ZFN comprises a non-naturally occurring zinc finger protein (ZFP) that binds to said target site in the EPSPS gene, wherein the ZFP comprises the recognition helix regions designated and ordered as set forth in any single row of Table A.

2. The method of claim 1 , wherein the homologous recombination results in a deletion within the DNA segment.

3. The method of claim 2 , wherein the deleted DNA sequence is replaced by an exogenous sequence, the method further comprising:

introducing a polynucleotide comprising the exogenous sequence into the cell, wherein the polynucleotide comprises at least a first and a second region of homology to the EPSPS gene, said regions of homology flanking the exogenous sequence.

4. The method of claim 3 , wherein the exogenous sequence encodes a selectable marker.

5. The method of claim 4 , wherein the selectable marker is selected from the group consisting of green fluorescent protein, β-glucuronidase, phosphinothricin N-acetyl transferase, neomycin phosphotransferase, hygromycin phosphotransferase, β-lactamase, catechol dioxygenase, α-amylase, tyrosinase, β-galactosidase, luciferase, aequorin, nitrilase, acetolactate synthase, dihydrofolate reductase, dalapon dehalogenase, and anthranilate synthase.

6. The method of claim 3 , wherein the exogenous sequence is an EPSPS gene sequence.

7. The method of claim 6 wherein the EPSPS gene sequence comprises a mutation relative to the wild-type EPSPS sequence.

8. The method of claim 7 , wherein the mutation increases tolerance of a plant to herbicide glyphosate relative to a control plant.

Assignments (1)
CHANGE OF NAME Recorded Apr 18, 2019
From: SANGAMO BIOSCIENCES, INC.
To: SANGAMO THERAPEUTICS, INC.
Reel/Frame 048945/0320 →
Continuity (4)
Continuation 13766380 · Feb 13, 2013
Division 12284888 · Sep 25, 2008
Provisional Application 60995557 · Sep 27, 2007
Related Publication 20150064790A1 · Mar 5, 2015